Indianapolis: Schrodinger has announced that it will offer Eli Lilly and Company’s artificial intelligence based drug discovery platform to users of its software, in a move aimed at speeding up early stage drug research.
Under the collaboration, Lilly’s ai platform known as Tunelab will be integrated into Schrodinger’s cloud based LiveDesign software. This will allow pharmaceutical and biotechnology researchers to use advanced ai tools alongside Schrodinger’s existing molecular modelling and simulation capabilities.
Schrodinger said the integration will help scientists design and test potential drug molecules more quickly by using machine learning models trained on large sets of research data. The combined platform is expected to reduce the time and cost involved in identifying promising drug candidates in the early phases of development.
According to the companies, existing LiveDesign customers will begin getting access to Tunelab in the first quarter of 2026, while new users are expected to gain access later in the year. The platform is designed with a strong focus on data privacy, using a federated learning approach that allows companies to benefit from shared learning without exposing confidential research data.
Eli Lilly said offering its ai technology through Schrodinger’s widely used software will help extend the reach of its drug discovery tools beyond its own laboratories. The company has been increasing its use of artificial intelligence to improve research productivity and strengthen its drug development pipeline.
The partnership reflects a wider trend in the pharmaceutical industry, where companies are turning to ai and advanced computing to improve success rates in drug discovery and reduce reliance on lengthy and expensive traditional methods.
Schrodinger, which has been shifting its focus more strongly toward software and artificial intelligence, said the collaboration strengthens its position as a key technology provider for modern drug research.